90 related articles for article (PubMed ID: 2165448)
21. Revision of requirements applicable to albumin (human), plasma protein fraction (human), and immune globulin (human); companion document to direct final rule. Food and Drug Administration, HHS. Proposed rule.
Fed Regist; 1999 May; 64(93):26344-8. PubMed ID: 10558531
[TBL] [Abstract][Full Text] [Related]
22. Safety of immune globulins in relation to HTLV-III.
FDA Drug Bull; 1986 Jun; 16(1):3. PubMed ID: 3015704
[TBL] [Abstract][Full Text] [Related]
23. Prevention of cytomegalovirus infection in bone marrow transplant recipients by prophylaxis with an intravenous, hyperimmune cytomegalovirus globulin.
Condie RM; O'Reilly RJ
Birth Defects Orig Artic Ser; 1984; 20(1):327-44. PubMed ID: 6329370
[No Abstract] [Full Text] [Related]
24. Prophylactic use of anti-CMV immunoglobulins in heart transplant recipients: a study on its safety.
Metselaar HJ; Velzing J; Rothbarth PH; Balk AH; Mochtar B; Weimar W
Transplant Proc; 1989 Feb; 21(1 Pt 3):2504-5. PubMed ID: 2539677
[No Abstract] [Full Text] [Related]
25. Prevention of cytomegalovirus disease in heart transplant recipients by prophylaxis with cytomegalovirus hyperimmune globulin plus oral acyclovir.
Eisenmann D; Knipp H; Laube H; Stegmann T
Transplant Proc; 1990 Oct; 22(5):2322-3. PubMed ID: 2171169
[No Abstract] [Full Text] [Related]
26. Criteria for use of intravenous immune globulin (IVIG).
Renfro WH; Paryani SG
Clin Pharm; 1990 Jul; 9(7):550-2. PubMed ID: 2198126
[No Abstract] [Full Text] [Related]
27. Revision of requirements applicable to albumin (human), plasma protein fraction (human), and immune globulin (human). Food and Drug Administration, HHS. Direct final rule.
Fed Regist; 1999 May; 64(93):26282-7. PubMed ID: 10558530
[TBL] [Abstract][Full Text] [Related]
28. Review of the efficacy of cytomegalovirus immune globulin in the prophylaxis of CMV disease in renal transplant recipients.
Snydman DR
Transplant Proc; 1993 Oct; 25(5 Suppl 4):25-6. PubMed ID: 8212304
[No Abstract] [Full Text] [Related]
29. Meta-analysis of immune globulin prophylaxis in transplant recipients for the prevention of symptomatic cytomegalovirus disease.
Glowacki LS; Smaill FM
Transplant Proc; 1993 Feb; 25(1 Pt 2):1408-10. PubMed ID: 8382863
[No Abstract] [Full Text] [Related]
30. Somebody else's antibodies: the characteristics and roles of immune globulins.
Grabenstein JD
Pharm Pract Manag Q; 2001; 20(3):41-55; quiz 56-9. PubMed ID: 11291518
[TBL] [Abstract][Full Text] [Related]
31. Revision to requirements for licensed Anti-Human Globulin and Blood Grouping Reagents. Food and Drug Administration, HHS. Direct final rule.
Fed Regist; 2000 Dec; 65(239):77497-9. PubMed ID: 11503726
[TBL] [Abstract][Full Text] [Related]
32. Cytomegalovirus infection in bone marrow transplant recipients: use of intravenous gamma globulin as a prophylactic and therapeutic agent.
Kapoor N; Copelan EA; Tutschka PJ
Transplant Proc; 1989 Feb; 21(1 Pt 3):3095-6. PubMed ID: 2539686
[No Abstract] [Full Text] [Related]
33. FDA approves ultra-sensitive test. Food and Drug Administration.
Vazquez E
Posit Aware; 1999; 10(3):22. PubMed ID: 11366759
[TBL] [Abstract][Full Text] [Related]
34. Cytomegalovirus immune globulin.
Med Lett Drugs Ther; 1988 Oct; 30(777):100. PubMed ID: 2845236
[No Abstract] [Full Text] [Related]
35. FDA notifications. FDA tentatively approves 3-drug tablet in India.
AIDS Alert; 2007 Apr; 22(4):43. PubMed ID: 17598192
[No Abstract] [Full Text] [Related]
36. Successful treatment of severe cytomegalovirus infections with ganciclovir and CMV hyperimmune globulin in liver transplant recipients.
D'Alessandro AM; Pirsch JD; Stratta RJ; Sollinger HW; Kalayoglu M; Belzer FO
Transplant Proc; 1989 Jun; 21(3):3560-1. PubMed ID: 2545018
[No Abstract] [Full Text] [Related]
37. Revision of requirements applicable to albumin (human), plasma protein fraction (human), and immune globulin (human); confirmation in part and technical amendment. Food and Drug Administration, HHS. Direct final rule; confirmation in part and technical amendment.
Fed Regist; 2000 Mar; 65(50):13678-9. PubMed ID: 11010647
[TBL] [Abstract][Full Text] [Related]
38. FDA notifications. FDA approves new Kaletra formulation.
AIDS Alert; 2005 Dec; 20(12):142-3. PubMed ID: 16400722
[No Abstract] [Full Text] [Related]
39. Combination antiviral strategies in managing cytomegalovirus infection.
Martin M
Transplant Proc; 1994 Oct; 26(5 Suppl 1):28-30. PubMed ID: 7940973
[No Abstract] [Full Text] [Related]
40. FDA notifications. FDA approves generic stavudine.
AIDS Alert; 2009 Mar; 24(3):34. PubMed ID: 19441156
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
